---
title: "Hengrui Pharmaceuticals' Unit Gets Nod for HRS9531 Injection Clinical Trials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280731966.md"
description: "Hengrui Pharmaceuticals' Unit Gets Nod for HRS9531 Injection Clinical Trials"
datetime: "2026-03-27T05:20:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280731966.md)
  - [en](https://longbridge.com/en/news/280731966.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280731966.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/280731966.md) | [繁體中文](https://longbridge.com/zh-HK/news/280731966.md)


# Hengrui Pharmaceuticals' Unit Gets Nod for HRS9531 Injection Clinical Trials

Hengrui Pharmaceuticals' Unit Gets Nod for HRS9531 Injection Clinical Trials

### Related Stocks

- [Hengrui Pharma (600276.CN)](https://longbridge.com/en/quote/600276.CN.md)
- [HENGRUI PHARMA (01276.HK)](https://longbridge.com/en/quote/01276.HK.md)
- [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/en/quote/516820.CN.md)

## Related News & Research

- [Hengrui Pharmaceutical Gets China Nod for Type 2 Diabetes Injectable](https://longbridge.com/en/news/279234349.md)
- [Hengrui Pharma Gets Nod for Solid Tumor Injection's Clinical Trials](https://longbridge.com/en/news/273791098.md)
- [Changchun High-Tech's Subsidiary Gets China Nod for GenSci161 Injection Trial](https://longbridge.com/en/news/281309555.md)
- [Huadong Medicine's Unit Gets Nod for HDM2024 for Injection's Clinical Trial](https://longbridge.com/en/news/280745131.md)
- [Biokin Pharmaceutical Gets Nod to Trial BL-ARC002 Injection; Shares Down 4%](https://longbridge.com/en/news/280094058.md)